Brief: Tg Therapeutics Announces European Commission Approval For Briumvi® (Ublituximab-Xiiy) For The Treatment Of Relapsing Forms Of Multiple Sclerosis In Adults
01/06/2023 14:20
June 1 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR
BRIUMVI® (UBLITUXIMAB-XIIY) FOR THE TREATMENT OF RELAPSING FORMS
OF MULTIPLE SCLEROSIS IN ADULTS
Source text for Eikon: ID:nGNX1BPhcD
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj